The cohort included 687 patients and 2971 dental implants. The study group (PPIs users) comprised 17.3% (119) individuals and 18.7% (555) implants. Only subjects who continuatively used one of the PPI (ATC code A02BC, i.e., omeprazole, pantoprazole, lansoprazole, dexlansoprazole, esomeprazole, rabeprazole, dexrabeprazole, or a combination of these)) for at least 1 year were included in the study group.
The remaining cohort (82.7% (568) individuals and 81.3% (2416) implants) served as control.
All the implants used were two-p, iece, internal hex, rough surface titanium (Tapered ® Screw-Vent Implant System, Zimmer Dental, (Warsaw, IN, USA); Lance®, MIS, (Bar Lev Industrial Park BAR-LEV, 2015600 Israel); MPI®, Ditron Dental, 2 Haofe St. South ind. Zone P.O.B 5010 Ashkelon 7815001 Israel). All treatments were performed by experienced oral and maxillofacial surgeons and prosthodontists. The study protocol was approved by the ethics committee of the Rabin Medical Center, Campus Beilinson, Israel (0674-19rmc). The present script complies with the STROBE guidelines [15 (link)]. Dental records of all individuals included were extracted and manually screened twice by 2 examiners (DM and LC).
The following information was collected: age, gender, physical status, systemic diseases, HbA1C values before and after implant-supported prosthesis delivery in cases of diabetes mellitus, smoking, implant location, number of implants per individual, bone augmentation, implant brand, length and width, and EIF.
EIF was defined as implant removal within a period of up to 12 months from loading.
The remaining cohort (82.7% (568) individuals and 81.3% (2416) implants) served as control.
All the implants used were two-p, iece, internal hex, rough surface titanium (Tapered ® Screw-Vent Implant System, Zimmer Dental, (Warsaw, IN, USA); Lance®, MIS, (Bar Lev Industrial Park BAR-LEV, 2015600 Israel); MPI®, Ditron Dental, 2 Haofe St. South ind. Zone P.O.B 5010 Ashkelon 7815001 Israel). All treatments were performed by experienced oral and maxillofacial surgeons and prosthodontists. The study protocol was approved by the ethics committee of the Rabin Medical Center, Campus Beilinson, Israel (0674-19rmc). The present script complies with the STROBE guidelines [15 (link)]. Dental records of all individuals included were extracted and manually screened twice by 2 examiners (DM and LC).
The following information was collected: age, gender, physical status, systemic diseases, HbA1C values before and after implant-supported prosthesis delivery in cases of diabetes mellitus, smoking, implant location, number of implants per individual, bone augmentation, implant brand, length and width, and EIF.
EIF was defined as implant removal within a period of up to 12 months from loading.
Free full text: Click here
